Krystal Biotech, Inc.

NasdaqGS:KRYS 株式レポート

時価総額：US$5.5b

Krystal Biotech マネジメント

マネジメント 基準チェック /44

Krystal Biotechの CEO はKrish Krishnanで、 Dec2015年に任命され、 の在任期間は 8.92年です。 の年間総報酬は$ 6.22Mで、 11.8%給与と88.2%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の5.43%を直接所有しており、その価値は$ 297.45M 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と6.4年です。

主要情報

Krish Krishnan

最高経営責任者

US$6.2m

報酬総額

CEO給与比率11.8%
CEO在任期間8.9yrs
CEOの所有権5.4%
経営陣の平均在職期間2.8yrs
取締役会の平均在任期間6.4yrs

経営陣の近況

Recent updates

Krystal Biotech, Inc. (NASDAQ:KRYS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Nov 07
Krystal Biotech, Inc. (NASDAQ:KRYS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On

Oct 14

Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)

Jul 31

Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think

May 13
Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think

Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch

Feb 28

Krystal Biotech: Ready For Launch

Feb 20

We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth

Jan 02
We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth

Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth

Sep 06
Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth

Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?

Aug 08
Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

May 17
We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Jan 30
We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Krystal Biotech cleared to file EU marketing application for rare skin disease therapy

Sep 22

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

Aug 30
We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

Krystal Biotech: Solid Performance, Let's Keep Holding

Aug 18

Krystal Biotech GAAP EPS of -$1.10 misses by $0.07

Aug 08

Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis

Aug 01

Krystal Biotech: High Potential, Buy-At-Dips Stock

May 25

We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Apr 20
We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Krystal Biotech: The Future Looks More And More Derisked

Feb 21

Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications

Nov 30

Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout

Sep 27

Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation

Sep 25
Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation

CEO報酬分析

Krystal Biotech の収益と比較して、Krish Krishnan の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

US$52m

Jun 30 2024n/an/a

US$106m

Mar 31 2024n/an/a

US$57m

Dec 31 2023US$6mUS$733k

US$11m

Sep 30 2023n/an/a

-US$30m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$135m

Dec 31 2022US$3mUS$645k

-US$140m

Sep 30 2022n/an/a

-US$130m

Jun 30 2022n/an/a

-US$115m

Mar 31 2022n/an/a

-US$104m

Dec 31 2021US$7mUS$581k

-US$70m

Sep 30 2021n/an/a

-US$58m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$43m

Dec 31 2020US$764kUS$498k

-US$32m

Sep 30 2020n/an/a

-US$27m

Jun 30 2020n/an/a

-US$22m

Mar 31 2020n/an/a

-US$20m

Dec 31 2019US$631kUS$366k

-US$19m

Sep 30 2019n/an/a

-US$17m

Jun 30 2019n/an/a

-US$16m

Mar 31 2019n/an/a

-US$13m

Dec 31 2018US$705kUS$200k

-US$11m

Sep 30 2018n/an/a

-US$9m

Jun 30 2018n/an/a

-US$11m

Mar 31 2018n/an/a

-US$10m

Dec 31 2017US$69kUS$69k

-US$8m

報酬と市場: Krishの 総報酬 ($USD 6.22M ) は、 US市場 ($USD 7.74M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Krishの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Krish Krishnan (59 yo)

8.9yrs

在職期間

US$6,223,894

報酬

Mr. Krish S. Krishnan, M.S., M.B.A., is Founder of Krystal Biotech, Inc. since December 2015. He has been President, Chief Executive Officer and Chairman at Krystal Biotech, Inc. since December 2015. Mr. K...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Krish Krishnan
Founder8.9yrsUS$6.22m5.43%
$ 297.5m
Suma Krishnan
Founder8.9yrsUS$3.84m5.53%
$ 302.9m
Kathryn Romano
Executive VP & Chief Accounting Officer4.8yrsUS$2.57m0.045%
$ 2.5m
John Thomas
General Counsel & Corporate Secretaryno dataデータなしデータなし
John Karakkal
Vice President of North American Sales & Marketingno dataデータなしデータなし
Christine Wilson
Head of U.S. Sales & Marketingless than a yearデータなしデータなし
Stephane Paquette
Vice President of Corporate Developmentno dataデータなしデータなし
Josh Suskin
Director of Human Resources & Operationsno dataデータなしデータなし
Laurent Goux
Senior VP & GM of Europeno dataデータなしデータなし
David Chien
Senior Vice President of Clinical Development2.8yrsデータなしデータなし
Jennifer McDonough
Senior Vice President of Patient Accessless than a yearデータなしデータなし
Ramesh Arjunji
Senior Vice President of Global Value and Accessless than a yearデータなしデータなし

2.8yrs

平均在職期間

59yo

平均年齢

経験豊富な経営陣: KRYSの経営陣は 経験豊富 であると考えられます ( 2.8年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Krish Krishnan
Founder8.9yrsUS$6.22m5.43%
$ 297.5m
Suma Krishnan
Founder8.8yrsUS$3.84m5.53%
$ 302.9m
Daniel Janney
Lead Independent Director8yrsUS$610.32k0.37%
$ 20.4m
Dino Rossi
Independent Director7.4yrsUS$584.82k0.27%
$ 15.0m
Julian Gangolli
Independent Director5.7yrsUS$585.07kデータなし
E. Sutherland
Independent Director2.8yrsUS$570.44k0%
$ 0
Christopher Mason
Independent Director3.8yrsUS$568.32k0%
$ 0
Kirti Ganorkar
Non-Employee Independent Director7.2yrsデータなしデータなし
Catherine Mazzacco
Independent Director1.7yrsUS$934.43k0%
$ 0
Samuel Broder
Chairman of Scientific Advisory Board4.8yrsデータなしデータなし

6.4yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: KRYSの 取締役会 は 経験豊富 であると考えられます ( 6.4年の平均在任期間)。